Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

INFECTION

Understanding clinical variables to improve empirical antibiotic therapy for UTI

Nature Reviews Urology volume 16, pages 695–696 (2019)Cite this article

Subjects

A recent study showed a correlation between clinical patient features and antibiotic resistance in patients with urinary tract infection (UTI). As resistance to antibiotics cannot be reversed, managing its emergence is of the utmost importance. Improving surveillance data will enable selection of appropriate antibiotics and help reduce the development of resistance.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Yelin, I. et al. Personal clinical history predicts antibiotic resistance of urinary tract infections. Nat. Med. 25, 1143–1152 (2019).

    Article  CAS  Google Scholar 

  2. Sundqvist, M. et al. Little evidence for reversibility of trimethoprim resistance after a drastic reduction in trimethoprim use. J. Antimicrob. Chemother. 65, 350–360 (2010).

    Article  CAS  Google Scholar 

  3. Eliakim-Raz, N. et al. Risk factors for treatment failure and mortality among hospitalized patients with complicated urinary tract infection: a multicenter retrospective cohort study (RESCUING Study Group). Clin. Infect. Dis. 68, 29–36 (2019).

    PubMed  Google Scholar 

  4. Tandog˘du, Z. et al. Antimicrobial resistance in urosepsis: outcomes from the multinational, multicenter global prevalence of infections in urology (GPIU) study 2003–2013. World J. Urol. 34, 1193–1200 (2016).

    Article  Google Scholar 

  5. Paul, M. et al. Improving empirical antibiotic treatment using TREAT, a computerized decision support system: cluster randomized trial. J. Antimicrob. Chemother. 58, 1238–1245 (2006).

    Article  CAS  Google Scholar 

  6. Tandogdu, Z. et al. Appropriate empiric antibiotic choices in health care associated urinary tract infections in urology departments in Europe from 2006 to 2015: a Bayesian analytical approach applied in a surveillance study. PLOS ONE 14, e0214710 (2019).

    Article  CAS  Google Scholar 

  7. Haldrup, S. et al. Microbiological point of care testing before antibiotic prescribing in primary care: considerable variations between practices. BMC Fam. Pract. 18, 9 (2017).

    Article  Google Scholar 

  8. Fritzenwanker, M. et al. Modern diagnostic methods for urinary tract infections. Expert Rev. Anti. Infect. Ther. 14, 1047–1063 (2016).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinic for Urology, Pediatric Urology and Andrology, Justus-Liebig University, Giessen, Germany

    Florian M. Wagenlehner

  2. Department of Urology, Technical University of Munich, Munich, Germany

    Kurt G. Naber

Authors
  1. Florian M. Wagenlehner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kurt G. Naber
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Florian M. Wagenlehner or Kurt G. Naber.

Ethics declarations

Competing interests

F.M.W. declares personal fees and other from Bionorica, during the conduct of the study; personal fees and other from Achaogen, personal fees from AstraZeneca, personal fees and other from Bionorica, other from Enteris BioPharma, other from Helperby Therapeutics, personal fees from Janssen, personal fees from LeoPharma, personal fees from MerLion, personal fees from Merck Sharp and Dohme (MSD), personal fees and other from OM Pharma/Vifor Pharma, personal fees from Pfizer, personal fees from RosenPharma, personal fees and other from Shionogi, personal fees from VenatoRx, personal fees from GlaxoSmithKline (GSK) and other from Deutsches Zentrum für Infektionsforschung (DZIF) (Giessen-Marburg-Langen site), outside the submitted work. K.G.N declares personal fees from Adamed, personal fees from Allecra, personal fees from Apogepha, personal fees from Aristo, personal fees from Bionorica, personal fees from Biomerieux, personal fees from Enteris, personal fees from GlaxoSmithKline, personal fees from Gruenenthal Mexico, personal fees from Helperby, personal fees from Marpinion, personal fees from MerLion, personal fees from Medice, non-financial support from Mission Pharmacal, personal fees from MSD, personal fees from OM Pharma/Vifor, personal fees from Paratek, personal fees from Roche, personal fees from Saxonia and personal fees from Zambon, outside the submitted work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wagenlehner, F.M., Naber, K.G. Understanding clinical variables to improve empirical antibiotic therapy for UTI. Nat Rev Urol 16, 695–696 (2019). https://doi.org/10.1038/s41585-019-0240-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-019-0240-0

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing